TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35050203
Drug: Standardized high-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized high-fat meal containing 75 g of fat (70% fat)
Study: 32236212
Drug: Cocoa supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa supplementation (5 g daily, 425 mg of flavanols)
Study: 32484533
Drug: Tablet-based decision
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based decision support tool prior to 25 weeks' gestation
Study: 34076601
Drug: Oral ASA
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ASA 300 mg
Study: 34076601
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine acetylsalicylate 150 mg
Study: 33582692
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 2 mg/kg Bupivacaine (Group A)
Study: 35110315
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg TXA
Study: 35854106
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (300 mg once a day for 8 weeks)
Study: 33308329
Drug: Prompt provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt provision of clozapine for patients with treatment-resistant schizophrenia
Study: 33308329
Drug: Universal provision
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal provision of cognitive-behavioural therapy for patients at clinical high risk of psychosis
Study: 32444041
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg tablet daily)
Study: 32444041
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch preparation)
Study: 33736674
Drug: Kai-Hou-Jian spray
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kai-Hou-Jian spray (children’s type)
Study: 35897081
Drug: MMPR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMPR plus sub‐dissociative ketamine infusion
Study: 34787719
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preparation and filling)
Study: 33216360
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of drug
Study: 34644317
Drug: Azithromycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (100 mg for three days, given on four occasions at monthly intervals)
Study: 37610727
Drug: Written Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written Exposure Therapy (WET)
Study: 33883876
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of estradiol (E2) and dydrogesterone (DG)
Study: 38795110
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice daily
Study: 36335914
Drug: Apixaban pharmacokinetics
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban pharmacokinetics
Study: 34715057
Drug: Infliximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (10 mg/kg over 2 hours without premedication)
Study: 34715057
Drug: Second IVIG
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second IVIG (2 g/kg over 8-12 hours)
Study: 34715057
Drug: IVIG (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (as either first or second treatment)
Study: 34119470
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous iron therapy
Study: 34119470
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous iron therapy
Study: 35438782
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily (cohort 1)
Study: 35438782
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily + Paclitaxel 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle (cohort 2)
Study: 35438782
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily + Paclitaxel 80 mg/m2 (cohort 2)
Study: 35147758
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy using Siriraj in-house-developed frozen gloves worn during chemotherapy administration.
Study: 35147758
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cold therapy).
Study: 35147758
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy using frozen gloves.
Study: 35194005
Drug: G‐chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐chemo
Study: 32054508
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline spray followed by a fluorinated steroid spray daily for six months (medical management).
Study: 35380650
Drug: Hospital-based comprehensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based comprehensive medication reviews including postdischarge follow-up
Study: 33271049
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) for participants who denied head injuries but reported serious nonhead injuries (NHI).
Study: 33271049
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) for participants who denied any injury (NI).
Study: 32508213
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (methylphenidate)
Study: 35953245
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg daily
Study: 32537688
Drug: rHuEPO (epoetin-β;
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (epoetin-β; mean dose 6000 IU per week)
Study: 32331030
Drug: Deutetrabenazine 12
Normalized name: deutetrabenazine 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 12 mg/day, titrating up to a maximum total daily dose of 48 mg/day based on dyskinesia control and tolerability.
Study: 32278029
Drug: Tongguan Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan Capsules (TGC) 4.5 g/d for 6 months
Study: 32278029
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for MI
Study: 34996820
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (Control group)
Study: 32437192
Drug: Caffeine 1
Normalized name: caffeine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 1 mg/kg
Study: 34284351
Drug: Caffeine 2
Normalized name: caffeine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2 mg/kg
Study: 33932130
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg
Study: 35512918
Drug: Warfarin patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin patients
Study: 34915738
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase before thrombectomy (combination treatment)
Study: 35897371
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shockwave therapy (r‐ESWT)
Study: 32407654
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg‐1)
Study: 32826171
Drug: HDR-BRT (High-Dose-Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDR-BRT (High-Dose-Rate Brachytherapy)
Study: 33383348
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy followed by total mesorectal excision and postoperative chemotherapy (standard arm), N = 623
Study: 33853802
Drug: Weekly menu
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly menu box delivery service including all ingredients and recipes for morning snack, lunch, and afternoon snack, developed by dietitians and meeting menu planning guidelines.
Study: 32876405
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg (group T)
Study: 33342003
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with testosterone replacement therapy plus alternate-day tadalafil (10 mg)
Study: 35190177
Drug: Nivolumab (N;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (N; 3 mg/kg intravenously on days 1, 15, and 29; n=23)
Study: 35190177
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with Ipilimumab (NI; 1 mg/kg intravenously on day 1; n=21)
Study: 35190177
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chemotherapy or previously untreated patients)
Study: 35124285
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (CIMT)
Study: 34250977
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of CYD-TDV and quadrivalent HPV vaccine
Study: 32107364
Drug: Low-dose EC-MPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose EC-MPS
Study: 32107364
Drug: Standard-dose MZR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose MZR
Study: 35356618
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (4 weeks intervention)
Study: 37941050
Drug: Implants
Normalized name: Goserelin Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants
Study: 34129239
Drug: Warfarin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin monotherapy
Study: 34151820
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (no active treatment)
Study: 33504190
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of anticoagulant therapy
Study: 35355382
Drug: DEX-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX-implant
Study: 33850184
Drug: IFNβ1b (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ1b (subcutaneous injections of 8,000,000 IU on days 1, 3, 6)
Study: 34340527
Drug: THX‐110 (∆9‐THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: THX‐110 (∆9‐THC 10 mg daily and PEA 800 mg daily)
Study: 32827412
Drug: NR-INF-02 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NR-INF-02 (both doses)
Study: 34015499
Drug: Polyphenol-rich seaweed
Normalized name: seaweed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich seaweed extract (2000 mg/d)
Study: 35363205
Drug: Online rational
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online rational emotive behavior therapy (online REBT)
Study: 38775255
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine
Study: 35177279
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod (IMQ) therapy for 16 weeks
Study: 35091786
Drug: Daily self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-monitoring of blood pressure (BP) for 2 months
Study: 35091786
Drug: Multiple self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple self-monitoring (BP, body fat, sleeping time, daily step count) for 2 months
Study: 33100181
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment (low dose regimen, 40 mg)
Study: 38159908
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment
Study: 35997638
Drug: Control (non-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-treatment districts)
Study: 32306747
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (general practice medical care)
Study: 37612223
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors
Study: 34857420
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of bivalent HPV vaccine
Study: 39773759
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (ICBT)
Study: 34006388
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa (NS) oil soft gelatin capsules 450 mg twice daily
Study: 32349193
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg (subgroup with preserved LVEF)
Study: 33209056
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.1 mg/kg
Study: 35002315
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment).
Study: 35281316
Drug: YYD601 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD601 30 mg
Study: 35281316
Drug: YYD601 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD601 40 mg
Study: 35281316
Drug: YYD601 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD601 60 mg
Study: 36597163
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 50 mg/kg
Study: 33462323
Drug: Late implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late implant placement following alveolar ridge preservation (LP/ARP)
Study: 32998920
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intravenous dexamethasone
Study: 34263442
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DH)
Study: 32345649
Drug: cRGD-ZW800-1 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cRGD-ZW800-1 at 0.05 mg/kg
Study: 32345649
Drug: cRGD-ZW800-1 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cRGD-ZW800-1 at 0.005 mg/kg
Study: 32345649
Drug: cRGD-ZW800-1 at
Normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cRGD-ZW800-1 at 0.015 mg/kg
Study: 36181015
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg then 4 mg/kg/h)
Study: 33825411
Drug: Hemoheal cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoheal cream
Study: 32220893
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of post-induction mAF and post-induction mean mutant molecules per milliliter (mMMPM)
Study: 35600332
Drug: TCM decoction
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM decoction combined with acupuncture and moxibustion (A&M) treatment based on syndrome differentiation and treatment (SDT)
Study: 34455804
Drug: Isolate treatments
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolate treatments (Sclerotinia sclerotiorum) on fruit inoculation
Study: 34455804
Drug: Isolate treatments
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolate treatments (Sclerotinia sclerotiorum) on petiole inoculation
Study: 32954762
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency treatment of suprascapular and axillary nerves
Study: 32954762
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block treatment of suprascapular and axillary nerves
Study: 32954762
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block treatment
Study: 35587063
Drug: Nitazoxanide-based triple
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide-based triple therapy (nitazoxanide, proton pump inhibitor, and clarithromycin) for 14 days
Study: 35587063
Drug: Metronidazole-based standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole-based standard treatment (metronidazole, omeprazole, and clarithromycin) for 14 days
Study: 35587063
Drug: Nitazoxanide-based triple
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide-based triple therapy
Study: 32030454
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation (100% lavender oil for 3 minutes)
Study: 34048073
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral hygiene education (control group)
Study: 32678998
Drug: Manualised psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualised psychological treatment for tinnitus, details on dosage and duration not specified.
Study: 35850126
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of casirivimab and imdevimab
Study: 36050448
Drug: Trastuzumab (T)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (T) + Lapatinib (L)
Study: 33452180
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + Etanercept combination therapy
Study: 35860183
Drug: Algoplaque hydrocolloid
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algoplaque hydrocolloid dressing (AHD) combined with nanosilver antibacterial gel
Study: 32286686
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25 mg orally twice daily from days 8-12) + Clomiphene citrate (100 mg once daily from days 3-7)
Study: 32286686
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg once daily from days 3-7)
Study: 33485455
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg infusions at 2-week intervals)
Study: 33485455
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg infusions at 4-week intervals)
Study: 33738615
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture tele-therapy in addition to methotrexate and aerobic exercise training (group A)
Study: 32869576
Drug: Flunarizine Hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine Hydrochloride, 5 mg, once daily for 21 days.
Study: 32861015
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI), 4 sessions of behavioral therapy
Study: 32668505
Drug: Steroid-sparing antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-sparing antiemetic protocol using olanzapine (group 2)
Study: 32668505
Drug: Steroid-containing antiemetic
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-containing antiemetic protocol (group 1)
Study: 33713057
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac sodium
Study: 36459044
Drug: Benson's relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's relaxation therapy (BRT) plus aerobic exercise (5 sessions per week) for 8 weeks
Study: 36459044
Drug: Benson's relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's relaxation therapy (BRT) only for 8 weeks
Study: 33599720
Drug: Ontamalimab 75
Normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontamalimab 75 mg every 4 weeks for 72 weeks (OL1)
Study: 33599720
Drug: Ontamalimab 225
Normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontamalimab 225 mg every 4 weeks for 72 weeks (OL1)
Study: 33599720
Drug: Ontamalimab (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ontamalimab (combined data from both doses)
Study: 33147220
Drug: Amino acids-mineral
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids-mineral complexed (AACM) diet with 40, 40 and 2.75 mg/kg of Zn, Mn and Cu, respectively, plus 30, 30 and 5.25 mg/kg of Zn, Mn and Cu from AACM sources
Study: 35614161
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no treatment)
Study: 35385072
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (266 mg) + bupivacaine hydrochloride (100 mg)
Study: 35385072
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride (100 mg) alone
Study: 35084369
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg nightly for 3 days and then 300 mg twice a day for 11 days)
Study: 37186070
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/day
Study: 34548324
Drug: No parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parenteral nutrition